Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Inclusion Criteria: * Diagnosis of probable bvFTD * Centrally rated frontotemporal atrophy score of 2 or greater on brain MRI * MMSE ≥20 * Age \<80 years * Modified Hachinski ischemic score of ≤ 4 * Females, if of child-bearing potential, must practice true abstinence or be competent to use adequate contraception and agree to maintain this throughout the study * Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with national law is/are able to read, understand, and provide written informed consent * Has one (or more) identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥2 hours/day ≥3 days/week; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug * If currently taking an acetylcholinesterase inhibitor and/or memantine, the subject must have been taking such medication(s) for ≥3 months. The dosage regimen must have remained stable for ≥6 weeks and it must be planned to remain stable throughout participation in the study. * Able to comply with the study procedures Exclusion Criteria: * Significant central nervous system (CNS) disorder other than bvFTD * Significant intracranial pathology seen on brain MRI scan * Biomarker evidence of underlying Alzheimer's disease path…